Alexion Pharmaceuticals, Inc. (United States) is linked to 3 FDA-registered manufacturing sites. 18 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Alexion Pharmaceuticals, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/alexion-pharmaceuticals-inc

Overview

Alexion Pharmaceuticals, Inc., now a subsidiary of AstraZeneca, is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the development and delivery of innovative treatments. The company is particularly known for its work in research and development in the fields of hematology, nephrology, neurology, and metabolic disorders.

Core services & business areas

Drug DevelopmentBiotechnologyTherapeutic Solutions

Therapeutic areas

Registered manufacturing sites (3)

Physical sites registered with the US FDA and resolved to Alexion Pharmaceuticals, Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

18 FDA enforcement records linked to this company.

  • 4832025-03-07

    Failure to comply with REMS Implementation System

  • 4832024-11-07

    Late submission of an ICSR

  • 4832024-11-07

    Failure to develop written procedures

  • 4832024-11-07

    Late submission of 15-day report

  • 4832024-11-07

    Failure to review ADE information

  • 4832014-09-26

    Late submission of 15-day report

  • 4832014-09-26

    Late submission of annual safety reports

  • 4832014-08-22

    Procedures not in writing, fully followed

  • 4832014-08-22

    Supervisor Training/Education/Experience

  • 4832014-08-22

    Procedures for non-sterile drug products

  • recall — Class I2014-08-13

    Presence of Particulate Matter: Product failed the appearance for the presence of visible particles under labeled storage condition.

  • recall — Class I2014-02-05

    Presence of Particulate Matter: Failed the appearance test for the presence of visible particles.

  • warning_letter2013-03-22

    FDA Warning Letter (drug product)

  • 4832012-08-17

    Complaint Record required information

  • 4832012-08-17

    Training--operations, GMPs, written procedures

  • 4832012-08-17

    Complaint Handling Procedure

  • 4832010-04-21

    Failure to develop written procedures

  • 4832010-04-21

    Complaint Handling Procedure

For suppliers

Is this Alexion Pharmaceuticals, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.